Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer

Histopathology

Volumn 64, Issue 5, 2014, Pages 683-692

  Fong, Dominic ^a,b,c,d   Moser, Patrizia ^e   Kasal, Armin ^f   Seeber, Andreas ^a,b,d   Gastl, Guenther ^a,b   Martowicz, Agnieszka ^a,b   Wurm, Martin ^a   Mian, Christine ^f   Obrist, Peter ^g   Mazzoleni, Guido ^f   Spizzo, Gilbert ^a,b,c,d  

^a TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c FRANZ TAPPEINER HOSPITAL   (Italy)

^d Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^e MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^f CENTRAL HOSPITAL OF BOLZANO   (Italy)

^g Pathology Laboratory Zams   (Austria)

Author keywords

EpCAM; EpEX; EpICD; Immunohistochemistry; Pancreatic cancer

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TISSUE MICROARRAY; ADENOCARCINOMA; ANTIBODY SPECIFICITY; CHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROTEIN TERTIARY STRUCTURE; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896138209     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12307     Document Type: Article

References (28)

1. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007; 25; 1960-1966.
2. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011; 364; 1817-1825.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013; 369; 1691-1703.
4. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007; 171; 386-395.
5. Spizzo G, Fong D, Wurm M et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J. Clin. Pathol. 2011; 64; 415-420.
6. Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized Phase II/III trial. Int. J. Cancer 2010; 127; 2209-2221.
7. Schmidt M, Scheulen ME, Dittrich C et al. An open-label, randomized Phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann. Oncol. 2010; 21; 275-282.
8. Niedzwiecki D, Bertagnolli MM, Warren RS et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from calgb 9581. J. Clin. Oncol. 2011; 29; 3146-3152.
9. Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of Stage III colon cancer: a randomised study. Lancet 2002; 360; 671-677.
10. Maetzel D, Denzel S, Mack B et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat. Cell Biol. 2009; 11; 162-171.
11. Carpenter G, Red Brewer M. EpCAM: another surface-to-nucleus missile. Cancer Cell 2009; 15; 165-166.
12. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1a antigen (Ep-CAM). J. Mol. Med. (Berl.) 1999; 77; 699-712.
13. Varga M, Obrist P, Schneeberger S et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin. Cancer Res. 2004; 10; 3131-3136.
14. Spizzo G, Went P, Dirnhofer S et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res. Treat. 2004; 86; 207-213.
15. Schmidt M, Hasenclever D, Schaeffer M et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin. Cancer Res. 2008; 14; 5849-5855.
16. Benko G, Spajic B, Kruslin B, Tomas D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol. Oncol. 2013; 31; 468-474.
17. Stoecklein NH, Siegmund A, Scheunemann P et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 2006; 6; 165.
18. Seligson DB, Pantuck AJ, Liu X et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin. Cancer Res. 2004; 10; 2659-2669.
19. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH. Loss of Ep-CAM (co17-1a) expression predicts survival in patients with gastric cancer. Br. J. Cancer 2005; 92; 1767-1772.
20. Kimura H, Kato H, Faried A et al. Prognostic significance of EpCAM expression in human esophageal cancer. Int. J. Oncol. 2007; 30; 171-179.
21. Martowicz A, Spizzo G, Gastl G, Untergasser G. Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 2012; 12; 501.
22. Fong D, Steurer M, Obrist P et al. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J. Clin. Pathol. 2008; 61; 31-35.
23. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 2008; 26; 5630-5637.
24. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 2000; 80; 1943-1949.
25. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH, Nagtegaal ID. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod. Pathol. 2007; 20; 221-232.
26. Ralhan R, Cao J, Lim T, Macmillan C, Freeman JL, Walfish PG. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 2010; 10; 331.
27. Ralhan R, He HC, So AK et al. Nuclear and cytoplasmic accumulation of EP-ICD is frequently detected in human epithelial cancers. PLoS ONE 2010; 5; e14130.
28. Akita H, Nagano H, Takeda Y et al. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene 2011; 30; 3468-3476.